AETHLON MEDIC.NEW DL-001
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, … Read more
AETHLON MEDIC.NEW DL-001 (EJU) - Total Assets
Latest total assets as of December 2025: €8.06 Million EUR
Based on the latest financial reports, AETHLON MEDIC.NEW DL-001 (EJU) holds total assets worth €8.06 Million EUR as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AETHLON MEDIC.NEW DL-001 - Total Assets Trend (2020–2025)
This chart illustrates how AETHLON MEDIC.NEW DL-001’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AETHLON MEDIC.NEW DL-001 - Asset Composition Analysis
Current Asset Composition (March 2025)
AETHLON MEDIC.NEW DL-001's total assets of €8.06 Million consist of 80.8% current assets and 19.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 74.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €550.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how AETHLON MEDIC.NEW DL-001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AETHLON MEDIC.NEW DL-001's current assets represent 80.8% of total assets in 2025, a decrease from 96.7% in 2020.
- Cash Position: Cash and equivalents constituted 74.8% of total assets in 2025, down from 92.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 0.0% of total assets.
AETHLON MEDIC.NEW DL-001 Competitors by Total Assets
Key competitors of AETHLON MEDIC.NEW DL-001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
AETHLON MEDIC.NEW DL-001 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AETHLON MEDIC.NEW DL-001 generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AETHLON MEDIC.NEW DL-001 is currently not profitable relative to its asset base.
AETHLON MEDIC.NEW DL-001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.68 | 2.80 | 9.76 |
| Quick Ratio | 5.68 | 2.80 | 9.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.88 Million | € 3.19 Million | € 18.40 Million |
AETHLON MEDIC.NEW DL-001 - Advanced Valuation Insights
This section examines the relationship between AETHLON MEDIC.NEW DL-001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -10.8% |
| Total Assets | €7.36 Million |
| Market Capitalization | $446.12K USD |
Valuation Analysis
Below Book Valuation: The market values AETHLON MEDIC.NEW DL-001's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: AETHLON MEDIC.NEW DL-001's assets decreased by 10.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AETHLON MEDIC.NEW DL-001 (2020–2025)
The table below shows the annual total assets of AETHLON MEDIC.NEW DL-001 from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €7.36 Million | -10.75% |
| 2024-03-31 | €8.25 Million | -52.90% |
| 2023-03-31 | €17.51 Million | -9.83% |
| 2022-03-31 | €19.42 Million | +82.00% |
| 2021-03-31 | €10.67 Million | +2.71% |
| 2020-03-31 | €10.39 Million | -- |